论文部分内容阅读
介绍一种新放射性药物即钐［（１５３）￣Ｓｍ］－柠檬酸－羟基磷灰石（（１５３）￣Ｓｍ－Ｃｉｔｒａｔｅ－Ｈｙｄｒｏｘｙａｐａｔｉｔｅ），采用转换络合法进行标记。先将钐［（１５３）￣Ｓｍ］与柠檬酸络合，然后转换络合为羟基磷灰石（ＨＡ）的标记物。ＨＡ的络合容量约５ｍｇ（以Ｓｍ＿２Ｏ＿３计），标记物粒度主要为２—１０μｍ，标记率高达９８％。体外稳定性研究表明：标记物在生理盐水和人血浆蛋白溶液中放置三个半衰期，（１５３）￣Ｓｍ的总游离量小于２％。正常兔左后膝关节注射１４．８ＭＢｑ（４００μＣｉ）（１５３）￣Ｓｍ－Ｃｉｔｒａｔｅ－ＨＡ，于４８ｈ、７２ｈ、１２０ｈ处死，经各脏器取样测量没发现有明显的放射性计数，９９％的注射量滞留在关节内。本标记药物可望用作风湿性关节滑膜切除。
A new radiopharmaceutical samarium [(153) ¯Sm] -citrate-hydroxyapatite ((153) ¯Sm-Citrate-Hydroxyapatite) was introduced and labeled by conversion complex method. Samarium [(153) ~Sm] is first complexed with citric acid and then the label complexed to hydroxyapatite (HA) is converted. The complexing capacity of HA is about 5mg (Sm_2O_3). The particle size of HA is 2-10μm and the labeling rate is up to 98%. In vitro stability studies have shown that the marker has three half-lives placed in physiological saline and human plasma protein solutions, with a total free volume of less than 2% for (153) Sm. Normal rabbit left knee joint injection of 14.8MBq (400μCi) (153) ¯Sm-Citrate-HA, at 48h, 72h, 120h were killed, no significant radioactive counts were found by sampling the organs, 99% of the injection volume Stranded in the joints. This marker drug is expected to be used as a rheumatoid synovial resection.